Clinical trials: Respiratory Virus Infections
COVID-19
Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess immunogenicity and safety of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and…
- Trial name
- NCT04990544
- Testing
- 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose
- Where
- China
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
COVID-19
Safety and Efficacy of Mesenchymal Stem Cells in the Management of Severe COVID-19 Pneumonia
The disease caused by the new coronavirus, SARS-CoV-2, called COVID-19, it has considered a worldwide pandemia by the WHO. Suddently, it produces a lot of patients severe ill, in a little geographic area, that could surpase the…
- Trial name
- CELMA (NCT04429763)
- Testing
- Umbilical cord derived mesenchymal stem cells
- Volunteers
- 30 people
- Sponsor
- Trustem
Covid19
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital…
- Trial name
- COROMEC (NCT04678193)
- Testing
- Coromec Registry with ECL-19
- Where
- 3 sites in United States, India and 1 more
- Volunteers
- 27,000 people, healthy volunteers welcome
- Sponsor
- Aventyn, Inc.
COVID-19
AZD1222 Vaccine for the Prevention of COVID-19
The purpose of this study is to evaluate safety and immunogenicity of AZD1222 for COVID-19 prevention in the Russian Federation
- Trial name
- NCT04540393
- Testing
- AZD1222
- Where
- 4 sites in Russia
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
COVID-19, Cardiovascular Diseases
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
- Conditions
- COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- NCT04615949
- Testing
- Cannabidiol, pharmaceutically produced with < 5 ppm THC
- Where
- 20 sites in United States, Brazil and 1 more
- Volunteers
- 90 people
- Sponsor
- Cardiol Therapeutics Inc.
COVID-19, SARS-COV-2 Infection
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19.
- Trial name
- NCT07069309
- Testing
- BNT162b2 (2025/2026 recommended SARS-CoV-2 strain)
- Where
- 19 sites in United States
- Volunteers
- 774 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Corona Virus Infection, Covid19
Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells
This is an interventional new drug clinical trial for a Phase 2 randomized, double-blind, and placebo control study using intravenous injection of allogeneic adipose stem cells (Celltex AdMSCs) for subjects with severe COVID-19.
- Trial name
- AdMSCs (NCT05017298)
- Testing
- Allogeneic adipose-derived stem cells
- Volunteers
- 30 people
- Sponsor
- Celltex Therapeutics Corporation
Respiratory Syncytial Virus (RSV)
Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above
The purpose of this study is to assess the safety and immunogenicity of two dose levels of the single dose Recombinant RSV vaccine(CHO cells), when administered intramuscularly (IM) in healthy adults aged 18 years and older.
- Trial name
- NCT06642558
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose), Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)
- Where
- China
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Severe Influenza
Evaluate the Safety and Efficacy of Xiyanping in Pediatric Participants With Severe Influenza-Like Symptoms
This is a multicenter, randomized, open Label, add-on study.
- Trial name
- NCT03947411
- Testing
- Oseltamivir Phosphate, Xiyanping injection+Oseltamivir Phosphate
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
COVID-19, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
This is a multicenter, single-treatment study. Subjects will consist of adults with COVID-19 associated acute lung injury who are being cared for in a critical care environment.
- Trial name
- NCT04389671
- Testing
- Lucinactant
- Where
- 11 sites in United States, Argentina
- Volunteers
- 20 people
- Sponsor
- Windtree Therapeutics
Hepatitis B, Hepatitis C
Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India
This study will define the substantial disease burden associated with viral hepatitis in India, and provide a foundation to understand the host and viral determinants of disease pathogenesis that may ultimately impact treatment…
- Trial name
- NCT01772121
- Where
- 19 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Gilead Sciences
COVID-19
Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine
This is a randomized, placebo-controlled, two center, Phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and a double blind treatment phase to investigate the safety…
- Trial name
- COVID-19-101 (NCT04497298)
- Testing
- Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - Low dose, Two COVID-19 vaccine candidate (TMV-083/V-591) administrations - High dose, One COVID-19 vaccine candidate (TMV-083/V-591) administration - High dose
- Where
- 2 sites in Belgium, France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Influenza
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults
To perform a variety of assays on blood, serum, nasal wash samples and cells obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by…
- Trial name
- NCT00192192
- Testing
- CAIV-T
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects
- Trial name
- NCT01766921
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 1,393 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population
This is a multiple sites phase II trial, randomized, observer-blind, dose ranging, placebo-controlled study to evaluate the immunogenicity, safety, and tolerability of a single intramuscular injection of plant-based Seasonal VLP…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02236052
- Testing
- Non-adjuvanted low dose of quadrivalent VLP vaccine, Non-adjuvanted medium dose of quadrivalent VLP vaccine, Non-adjuvanted high dose of quadrivalent VLP vaccine
- Where
- 3 sites in Canada
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Medicago
Respiratory Syncytial Virus Infections
Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
The purpose of this study is to determine the safety, tolerability and efficacy of intranasal ALN-RSV01 versus placebo, administered once daily for 5 days to a healthy male volunteers experimentally inoculated with RSV
- Trial name
- NCT00496821
- Testing
- ALN-RSV01
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
COVID19
Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19
This randomized, Phase I/II feasibility study will evaluate the safety and efficacy of the RD-X19 device in SARS-CoV-2 infected individuals with uncomplicated COVID-19.
- Trial name
- NCT04662671
- Testing
- RD-X19
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- EmitBio Inc.
Respiratory Syncytial Virus Infections
A Dose Finding Study of VN-0200
This study will assess the immunogenicity, safety and tolerability of VN-0200 after intramuscular injections in Japanese healthy elderly subjects.
- Trial name
- NCT05547087
- Testing
- VN-0200
- Where
- 3 sites in Japan
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
SARS-CoV Infection
A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research
Minimal risk research study: 1. Comparing polyester nasal swabs and foam nasal swabs to detect SARS-CoV-2 virus; 2. Quantifying the development and trajectory of the disease through clinic visits and blood values.
- Trial name
- NCT04327804
- Testing
- Odd/Even birth year intervention groups
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- UnitedHealth Group
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.